IFN-γmethylation status SOCS1 methylation status
Variables U (n=7) U/M (n=59) M (n=30) P U (n=89) U/M (n=5) M (n=2) P
Age (Years) 40
(30-61)
48
(30-70)
50.5
(30-70)
0.49a 50
(30-70)
44
(30-65)
47.5
(35-60)
0.957a
Sex (M/F), n% 3/4
(42.9/5.1%)
35/24
(59.3/40.7%)
19/11
(63.3/36.7%)
0.61b 54/35
(60.7/39.3%)
3/2
(60/40%)
0/2
(0/100%)
0.225b
Creatinine (mg/dl) 9.1
(5.2-11.6)
8.57
(5-14.5)
6.3
4.2-14.33))
0.012a* 7.66
(4.2-14.5)
9
(5.2-11)
9.3
(7-11.6)
0.733a
eGFR
(ml/min/1.73 m2)
6.36
(3.96-9.79)
6.68
(2.86-13.91)
8.12
(3.46-14.09)
0.018a* 7.03
( 2.86-14.09)
7.29
(5.04-9.74)
5.16
(3.96-3.36)
0.366a
Hemodialysis Duration (Months) 24
(12-48)
36
(7-108)
24
(7-108)
0.62a 36
(7-108)
24
(12-36)
30
(24-36)
0.431a
Urea (mg/dl) 105
(62-144.32)
104.54
(54.5-186.9)
109.76
(51.1-184.5)
0.89a 105
(51.1-186.9)
95.45
(89.7-120.4)
99.77
(79.5-120)
0.947a
Total Cholesterol(mg/dl) 225.80
(122.5-264.5)
161.29
(103.2-332)
148.4
(103.23-310)
0.041a* 154.83
(103.23-332)
220
(141.9-258.06)
174.19
(122.6-225.8)
0.165a
Triglyceride(mg/dl) 166.66
(136.6-266.7)
166.66
(91.1-366.7)
145.32
(106.2-244.4)
0.20a 151.76
(91.1-327.8)
177.14
(151.7-366.67)
201.62
(136.6-266.7)
0.268a
HDL-C (mg/dl) 35.29
(30.88-39)
32.81
(20.59-60.2)
30.88
(21.88-47.06)
0.28a 32.35
(20.59-60.2)
32.35
(31-39.71)
35.14
(35-35.29)
0.790a
VLDL-C (mg/dl) 33.33
(27.32-53.33)
33.33
(18.21-73.3)
29.06
(21.25-48.9)
0.204a 30.35
(18.2-65.56)
35.42
(30.35-73.3)
40.32
(27.32-53.33)
0.268a
LDL-C (mg/dl) 149.11
(60.26-200.3)
92.13
(21.3-255.1)
80.58
(41.8-236.3)
0.103a 83.48
(21.3-255.1)
152.37
(74.8-190.56)
98.72
(60.3-137.2)
0.237a
Systolic BP(mm Hg) 180
(120-180)
150
(110-185)
140
(110-190)
0.26a 150
(110-190)
130
(120-180)
150
(120-180)
0.644a
Diastolic BP
(mm Hg)
95
(70-100)
90
(65-100)
90
(70-100)
0.14a 90
(65-100)
80
(70-100)
92.5
(85-100)
0.453a
Data are presented as median (range).
U Total unmethylation (only the unmethylated allele)
U/M Partial methylation (both unmethylated and methylated alleles)
M Total methylation (only the methylated allele)
aKruskal-Wallis test.
bChi-square test.
*Statistically significant compared at P<0.05.
eGFR estimated glomerular filtration rate.
Table 4: Correlation of IFN-γ and SOCS1promoter methylation with clinical and biochemical characteristics in ESRD patients.